Studies whether blood tests can predict response to cancer immunotherapy
Looks at blood DNA changes and tumor markers in adults with advanced cancer receiving immunotherapy.
Plain-language title generated from the registry record
Registry title: Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
Key facts
- Where
- Ho Chi Minh City, VietnamSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06227728, who can take part
Where in Vietnam
- Medical Genetics InstituteHo Chi Minh City, VietnamNot yet recruiting
- University of Medicine and Pharmacy at HCMCHo Chi Minh City, VietnamTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Gene Solutions
- Trial code
- NCT06227728
- Record updated
- 16 January 2026
- Original description
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.Read full original descriptionShow less
Analysis of PD-L1, TMB, CTDNA in Immunotherapy Response Monitoring and Prediction in Advancer Lung Cancer Treatment.
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.
Inclusion: 18 years and older, both genders; Patients are diagnosed with stage IV cancer (lung, colorectal, breast, liver, gastric…) and indicated for ICI (first or second line). Concurrent chemotherapy with ICI is allowed; FFPE/FNA sample is available; Compliant with treatment protocol; Patients consented to participate in the study.
Exclusion: Patients already started chemotherapy before enrollment; Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol; Patients already started ICI before enrollment; Consolidation ICI (eg. Durvalumab); Patients did not agree to participate in the studies.